Is it Time to Dump Allakos Inc (ALLK) Stock After it Is Higher By 14.88% in a Week?

The market has been high on Allakos Inc (ALLK) stock recently. ALLK gets a Bullish score from InvestorsObserver Stock Sentiment Indicator.

Allakos Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on ALLK!

See Full ALLK Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With ALLK Stock Today?

Allakos Inc (ALLK) stock is trading at $2.47 as of 10:29 AM on Wednesday, Sep 27, a gain of $0.30, or 14.12% from the previous closing price of $2.16. The stock has traded between $2.31 and $2.49 so far today. Volume today is less active than usual. So far 607,889 shares have traded compared to average volume of 1,346,164 shares.

More About Allakos Inc

Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK002, an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. In preclinical and clinical studies, AK002 has been shown to deplete eosinophils and inhibit mast cells. Click Here to get the full Stock Report for Allakos Inc stock.